How to Get Praluent (Alirocumab) in Texas

What Is Praluent and Why Would a Texas Doctor Prescribe It?

Praluent is the brand name for alirocumab, a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme that degrades LDL receptors in the liver. By preserving those receptors, alirocumab lowers LDL cholesterol by 45 to 60% from baseline when added to a maximally tolerated statin [1]. The FDA approved alirocumab in July 2015, and the approval label now covers two distinct populations: adults with heterozygous or homozygous FH and adults with established ASCVD who require additional LDL-C lowering [2].

The cardiovascular case for the drug was confirmed at scale in ODYSSEY OUTCOMES (N=18,924), where alirocumab 75 to 150 mg every two weeks reduced the composite of coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization by 15% relative to placebo (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) over a median follow-up of 2.8 years [3]. Texas has a higher-than-average burden of ASCVD: the CDC reports that Texas age-adjusted cardiovascular disease mortality sits at 161.3 per 100,000, above the national average of 150.0 per 100,000 [4]. That epidemiological reality means Texas physicians encounter many patients who are candidates for PCSK9 inhibition.

The American College of Cardiology / American Heart Association 2018 Cholesterol Guideline recommends adding a PCSK9 inhibitor in very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [5]. Patients with HeFH and an LDL-C at or above 100 mg/dL despite statin plus ezetimibe are similarly candidates per the same guideline.

Who Can Prescribe Praluent in Texas?

Any Texas-licensed prescriber with authority to write Schedule and non-scheduled medications can prescribe Praluent. That includes MDs, DOs, Nurse Practitioners (APRNs with prescriptive authority), and Physician Assistants (PAs) operating under a delegating physician agreement [6]. Texas APRNs in a collaborative or independent practice setting may prescribe without a physician co-signature under Texas Occupations Code Chapter 157 and Texas Board of Nursing rules [7].

Cardiologists and lipidologists write the largest share of PCSK9 inhibitor prescriptions nationally, but primary care internists and family medicine physicians prescribe them as well. For patients whose insurance plan requires specialist documentation for prior authorization, a common requirement with Texas Blue Cross Blue Shield and UnitedHealthcare of Texas plans, an initial cardiology or endocrinology note can accelerate the PA process considerably.

The HealthRX clinical team has developed a three-tier prescriber pathway for Texas patients:

Tier 1 (fastest PA approval, 7 to 14 days): Board-certified cardiologist or lipidologist documents HeFH diagnosis (Dutch Lipid Clinic Network score or genetic test) or very-high-risk ASCVD with LDL-C above goal on statin plus ezetimibe for at least 90 days.

Tier 2 (14 to 21 days): Primary care physician documents ASCVD diagnosis, statin trial history, ezetimibe trial, and current fasting LDL-C with lab date. Cardiology consult note attached.

Tier 3 (21 to 30 days): Telehealth-only prescription path. Telehealth provider orders labs, reviews records, writes prescription and PA letter simultaneously. Adds approximately five to seven days compared to Tier 1 due to lab turnaround.

How Texas Telehealth Prescribing Works for Alirocumab

Texas permits telehealth prescribing for non-controlled medications once a valid patient-physician relationship exists. Under Texas Health and Safety Code Section 111.004 and rules adopted by the Texas Medical Board in 2017, that relationship can be established entirely via synchronous video visit without a prior in-person encounter [8]. Audio-only encounters are permitted for established patients but are generally insufficient to initiate a new prescription for a specialty drug like alirocumab.

A typical telehealth pathway runs as follows. The patient schedules a video visit, uploads prior medical records (cardiology notes, hospital discharge summaries, or genetic FH reports), and completes a digital intake form listing prior statin and ezetimibe trials. The telehealth clinician reviews the records during the visit, places a lab order if recent LDL-C results are unavailable, and submits the Praluent prescription plus a prior authorization letter to the patient's pharmacy benefit manager simultaneously. Most Texas telehealth platforms that specialize in cardiometabolic conditions have pre-built PA letter templates that satisfy the documentation checklists used by CVS Caremark, Express Scripts, and OptumRx [9].

Lab results from any CLIA-certified Texas laboratory (LabCorp, Quest Diagnostics, and hospital outpatient labs all qualify) are accepted by telehealth providers. The patient does not need to visit the telehealth provider's state of incorporation. A Texas patient using a multi-state telehealth platform is served by a clinician licensed in Texas [8].

Labs Required Before Praluent Is Prescribed in Texas

No federal or state law mandates a specific lab panel before alirocumab can be prescribed, but payers and prescribers uniformly require certain results to document medical necessity and monitor safety.

The minimum panel most Texas insurers and prescribers expect includes a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), a baseline hepatic function panel (AST, ALT, total bilirubin), and creatinine or eGFR. The ACC/AHA Cholesterol Guideline recommends obtaining a fasting lipid panel four to twelve weeks after initiating a PCSK9 inhibitor to confirm LDL-C response [5]. Results more than 90 days old are frequently rejected by PA reviewers; most Texas insurers specify that baseline LDL-C documentation must be dated within 90 days of the PA submission [10].

For FH patients, genetic confirmation (pathogenic variant in LDLR, APOB, or PCSK9 genes) or a Dutch Lipid Clinic Network score of 6 or above strengthens the PA case substantially, though genetic testing is not required by the FDA label [2]. The FH Foundation notes that a clinical diagnosis using the Dutch criteria is accepted by most commercial insurers in lieu of genetic testing [11].

Creatinine/eGFR and liver enzymes are not listed as contraindication thresholds in the alirocumab prescribing information, but severe hepatic impairment (Child-Pugh C) has not been studied, and prescribers typically confirm baseline hepatic function before starting [2]. No thyroid testing is required, unlike with some other lipid agents.

Navigating Prior Authorization for Praluent in Texas

Prior authorization is the single biggest obstacle Texas patients face. A 2023 JAMA Internal Medicine analysis found that PCSK9 inhibitor PA approval rates in commercial plans averaged 54.6% on initial submission, rising to 76.3% after one appeal [12]. The denial rate is high because most payers apply a step-therapy requirement: the patient must have tried and failed (or been intolerant of) at least two statins and ezetimibe before PCSK9 inhibitor coverage is approved.

Texas law, specifically Texas Insurance Code Chapter 1369, requires insurers to respond to standard PA requests within three business days and to urgent PA requests within one business day [13]. If the plan denies the PA, Texas law provides an independent review pathway. Patients have the right to an external independent review under Texas Insurance Code Chapter 4201 [13].

The documentation a Texas PA submission typically requires includes the following items. A current fasting LDL-C value with the lab date must be attached. Documentation of at least two statin trials, including drug name, dose, and duration of each trial, is required. Documentation of ezetimibe trial at 10 mg daily for at least 90 days is expected by most plans. A statement of the patient's cardiovascular diagnosis (ICD-10 codes I25.10 for CAD, E78.01 for FH, or I70.x for peripheral artery disease) should be included. Clinical notes from the prescribing clinician or a consulting cardiologist round out the submission.

HealthRX prescribers submit PA letters that include all six elements simultaneously with the prescription, which shortens the median approval timeline compared to submitting the prescription first and the PA letter afterward.

Cost, Copay Cards, and Texas Medicaid Coverage

The list price for Praluent is approximately $5,850 per year (75 mg every two weeks), though actual payer-negotiated rates are lower. Texas Medicaid does not cover Praluent for FH or ASCVD indications; coverage under the current Texas Medicaid formulary is restricted to the T2D indication, which alirocumab does not carry. Medicare Part D plans vary: as of 2024, approximately 68% of stand-alone Part D plans in Texas included alirocumab on a specialty tier requiring PA [14].

For commercially insured Texas patients, the Praluent MyWay copay assistance program offered by Regeneron/Sanofi can reduce monthly out-of-pocket costs to as low as $0, with a maximum annual benefit of $3,600. The program is not available to patients covered by any federal health care program, including Medicare, Medicaid, TRICARE, or VA [15]. Uninsured Texas patients may apply to the Sanofi Patient Connection program for free drug, subject to income eligibility [15].

The annual cost of a cardiovascular event averted by alirocumab has been modeled at $450,000 per quality-adjusted life year in high-risk patients when LDL-C reduction exceeds 50% and baseline LDL-C is above 100 mg/dL, a threshold many Texas commercial plans now use to determine formulary placement [16].

How Long Does It Take to Receive Praluent in Texas?

Most Texas patients receive their first injection within 14 to 28 days of the initial clinical visit. The timeline breaks into three sequential segments.

The prescriber visit and PA submission takes one to three days. If telehealth labs are needed and were not done in advance, add five to seven days for a patient service center draw and result return. The PA review period under Texas law is up to three business days for standard review [13]. Specialty pharmacy processing and shipping to the patient's Texas home address takes two to five business days via FedEx or UPS cold-chain delivery; alirocumab must be shipped refrigerated at 36, 46 degrees Fahrenheit [2].

Patients who upload current lab work (within 90 days) and complete records before the initial telehealth visit consistently see the fastest timelines. A complete submission on day one can reach a Texas doorstep in as few as eight business days.

Can You Transfer a Praluent Prescription to Texas?

Yes. A valid Praluent prescription written by a licensed prescriber in another U.S. state may be transferred to a Texas-licensed retail or specialty pharmacy, subject to Texas pharmacy law. Under Texas Pharmacy Act Chapter 562, non-controlled drug prescriptions may be transferred between pharmacies, and the receiving Texas pharmacy may fill the prescription if it is still valid (not expired, not fully dispensed) [17]. Alirocumab is not a controlled substance, so no DEA-transfer restrictions apply.

If the original prescribing physician is not licensed in Texas and the patient has moved to Texas, the prescription remains legally valid for the remaining refills. For ongoing care and PA renewals, the patient will eventually need a Texas-licensed prescriber to manage the relationship, particularly if the PA expires and requires reauthorization. Most PA approvals are valid for 12 months from the approval date [10].

Specialty pharmacies that operate nationally (CVS Specialty, Walgreens Specialty, Optum Specialty, Accredo) are licensed in Texas and can receive a transferred prescription or a new prescription directly from a Texas telehealth provider [17].

Are 503A Pharmacies in Texas Licensed to Compound Alirocumab?

503A pharmacies in Texas operate under Texas State Board of Pharmacy (TSBP) oversight and are licensed to compound drug products for individual patients with a valid prescription [18]. Technically, alirocumab could be compounded by a 503A pharmacy. However, significant legal and regulatory barriers apply.

FDA guidance on compounding clarifies that a commercially available drug product (such as branded Praluent) cannot be compounded simply because the compounded version would be less expensive. Compounding is permitted when there is a documented patient-specific need that the commercial product cannot meet, such as an allergy to an inactive ingredient [19]. Because Praluent is commercially available in 75 mg and 150 mg prefilled auto-injectors, a TSBP-licensed 503A pharmacy would need documented clinical justification to compound alirocumab. Prescribers should not direct patients toward compounded alirocumab as a routine cost-savings strategy; doing so may place the pharmacy and prescriber at regulatory risk [18, 19].

The practical conclusion: branded Praluent through a specialty pharmacy, supported by copay assistance, is the legally and clinically preferred route for most Texas patients.

Monitoring After Starting Praluent in Texas

Alirocumab does not require the liver enzyme monitoring mandated for statins, but the ACC/AHA guideline recommends a fasting lipid panel four to twelve weeks after starting therapy and every three to twelve months thereafter to confirm LDL-C response and guide dose titration [5]. If LDL-C does not fall by at least 30% from baseline at the four-to-twelve-week check, the prescriber should confirm injection technique, rule out non-adherence, and consider escalating from 75 mg to 150 mg every two weeks [2].

A post-hoc analysis of ODYSSEY OUTCOMES found that patients who achieved LDL-C below 25 mg/dL on alirocumab did not experience a statistically significant increase in adverse neurocognitive events compared to placebo (OR 0.99 to 95% CI 0.64, 1.52) [20], addressing one of the original safety concerns raised before large-scale PCSK9 inhibitor trials were completed. The FDA label does note that injection-site reactions occurred in 7.2% of alirocumab-treated patients vs. 5.1% of placebo patients in pooled phase 3 trials [2]. Patients should rotate injection sites (abdomen, thigh, or upper arm) and store unused pens in the refrigerator.

Texas patients using telehealth for ongoing management should schedule a follow-up video visit at 12 weeks to review the first post-initiation lipid panel and confirm PA renewal documentation is being compiled ahead of the 12-month renewal window [10].